NEXGEL strategically recalled its entire SilverSeal inventory from Amazon, recording approximately $144,495 of associated Q2 expense as it prepares to reposition the wound-care product for a hospital-market launch that management expects to carry higher gross margins than its existing distribution channels.
The recall was not described as a product-safety action. Instead, NEXGEL said it deliberately removed the inventory from Amazon to support SilverSeal’s launch into the hospital channel beginning in August.
SilverSeal already has reimbursement A-codes, providing potential coverage opportunities across surgical and wound-care uses in physician offices, ambulatory surgery centers and hospitals. Management views the hospital channel as an opportunity to increase both sales volume and gross margin.
The repositioning comes during a broader transformation of NEXGEL following its April transaction with Celularity. The company has been integrating employees, sales representatives and customer relationships into the newly created BioNX Surgical division while coordinating its commercial strategy with Sequence Life Science.
That integration has progressed more slowly than originally anticipated. Supply-chain constraints have contributed to a BioNX Surgical backlog of approximately $795,000, while Sequence has deployed specialists to Celularity’s New Jersey facility to help transfer manufacturing technology and future production to San Antonio.
Q2 revenue totaled $3.69 million, while net loss was approximately $2.87 million. In addition to the $144,495 SilverSeal recall expense, the loss included $756,554 of BioNX intangible-asset amortization and $273,710 of one-time transaction costs.
NEXGEL is also extending BioNX beyond the surgical market. It recently launched BioNX Regenerative Eye Health & Aesthetics, which incorporates exclusively licensed Sequence products and targets ocular and aesthetic applications.
The company had approximately $710,000 of restricted cash at June 30 related to its prior ATW Partners transaction. Those funds were subsequently released back to NEXGEL, and the ATW business relationship has ended.
The SilverSeal decision is therefore part of a broader effort to move NEXGEL’s acquired and internally developed healthcare products toward institutional channels where reimbursement coverage and higher unit economics could potentially outweigh the loss of near-term Amazon sales.
